Bioretec Ltd, a pioneer in biodegradable orthopedic implants, has, as of August 7, 2023, appointed M.Sc. Esa Hallinen (56), as a director of operations and a member of the Management Team. In his role, Hallinen reports to the company's CEO.

Mr. Hallinen possesses over 15 years of experience in the development and manufacturing of medical devices, and packaging materials for the healthcare and food industry, including several years of experience in senior management positions in the plastics industry. In addition, his expertise covers all steps from concepts to large-scale manufacturing and commercialization from the perspective of product development, quality, and manufacturing in both growth and multinational companies.

"We are warmly welcoming Esa Hallinen to strengthen Bioretec Management Team and to lead our Tampere facility operations.  Esa will play a significant role in executing our growth strategy, considering his vast experience in operations management as well as his international experience in the development of medical devices. We also highly value his years of experience in the pharmaceutical industry," commented Bioretec CEO Timo Lehtonen.

Further enquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493

Johanna Salko, CFO, tel. +358 40 754 8172

Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE-mark is expected to be received during 2023. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment.

Better healing - Better life. www.bioretec.com